Advanced search
Publication Cover
Modern Rheumatology Volume 26, 2016 - Issue 4
Journal homepage
1,515
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, Correspondence[email protected]
,
Kazuhiko YamamotoDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan,
,
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan,
,
Naoki IshiguroDepartment of Orthopedic Surgery, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Aichi, Japan,
,
Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan,
,
Katsumi EguchiRheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan,
,
Akira WatanabeResearch Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan,
,
Hideki OrigasaDivision of Biostatistics and Clinical Epidemiology, The University of Toyama Graduate School of Medicine, Toyama, Japan,
,
Mariko KobayashiUCB Pharma, Shinjuku-ku, Tokyo, Japan,
,
Toshiharu ShojiUCB Pharma, Shinjuku-ku, Tokyo, Japan,
,
Osamu TogoUCB Pharma, Shinjuku-ku, Tokyo, Japan,
,
Nobuyuki MiyasakaTokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, and
&
Takao KoikeSapporo Medical Center NTT EC, Sapporo, Hokkaido, Japan
 show all
Pages 473-480 | Received 21 Jul 2015, Accepted 09 Oct 2015, Published online: 14 Dec 2015

References

  • Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol. 2014;24(4):552–60.
  • Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2014;24(5):715–24.
  • Keystone E, Heijde D, Mason D, Jr., Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319–29.
  • Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797–804.
  • Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2009;86(4):387–95.
  • Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod Rheumatol. 2014;24(5):734–43.
  • Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Mod Rheumatol. 2014;24(5):725–33.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
  • Cimzia (certolizumab pegol) prescribing information. 2013. Available from: http://www.cimzia.com/assets/pdf/MedicationGuide.pdf [last accessed 21 Jul 2015].
  • Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3):252–62.
  • Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauferon F, Ternant D, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13(3):R105.
  • Remicade (infliximab) prescribing information. 2013. Available from: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. [last accessed 21 Jul 2015].
  • Humira (adalimumab) prescribing information. 2014. Available from: http://www.rxabbvie.com/pdf/humira.pdf. [last accessed 21 Jul 2015].
  • Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod Rheumatol. 2015;25:11–20.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.